STOCKS TELEGRAPH

Tag: Teligent

  • A Rise In Teligent (TLGT) Stock In Early Trades: Why?

    A Rise In Teligent (TLGT) Stock In Early Trades: Why?

    In the current market trading session, Teligent Inc. (TLGT) advanced 4.74% at $0.63. During the previous trading session, Teligent stock gained 3.69% to close at $0.60. The TLGT stock was traded between $0.581 and $0.635. There were 3.01 million shares traded, which was below its daily average of 6.62 million shares over the past 100 days. Recent news could probably provide some insight since the TLGT stock wasn’t up for current news.

    Recent developments:

    Teligent is a generic pharmaceuticals specialty manufacturer. TLGT manufactures, markets, distributes, and sells generic topical pharmaceutical products, branded generic pharmaceuticals, and generic injectables in the United States and Canada. There are generic pharmaceutical products available by TLGT in topical, injectable, and ophthalmic dosage forms. In addition, Teligent is involved in liquid and semi-liquid topical pharmaceutical manufacturing, formulating, filling, and packaging for pharmaceutical and over-the-counter needs.

    Teligent’s Chief Financial Officer Ernest R. De Paolantonio was officially appointed this month and he took over on April 15, 2021.

    Mr. De Paolantonio has been a financial and business expert in the pharmaceutical industry for over 40 years. De Paolantonio most recently served as Chief Financial Officer of Fortovia Therapeutics, a private health care company that provided support for cancer patients and their families.

    Further compensations:

    In connection with the hiring of Mr. De Paolantonio, Teligent (TLGT)’s Board of Directors authorized the grant of 195,000 restricted stock units and 240,000 shares of TLGT Common Stock to Mr. De Paolantonio.

  • Why Teligent, Inc. (TLGT) stock is falling today?

    Why Teligent, Inc. (TLGT) stock is falling today?

    Shares of Teligent, Inc. (TLGT) stock were down today after rising  12.52% in the last trading session. TLGT stock price saw a downtrend of  4.27% to drop at  $0.6725 a share at the time of this writing. Let’s deep dive to understand the reason behind this fall.

    What’s happening?

    Teligent, Inc. is a pharmaceutical company working on the development, manufacturing, marketing, and selling of a variety of pharmaceutical products in the United States and Canada. There is no Teligent specific news to explain the reason behind this fall today. Even we find no news, earnings report, analyst downgrades, or shrank targeted per share price in the whole of March to connect with this fall. This is spreading curiosity among investors who are eager to hear some specific related to TLGT stock. So, it is better to look at some previous recent events of Teligent.

    February 2021 Events:

    Teligent, in February 2021, announced the new appointments in a couple of its management positions. On February 23, 2021, TLGT appointed Carter Pate to its Board of Directors. Mr. Pate is serving on the Board of Directors at various other companies and currently holding the responsibilities of Audit and Nominating and Corporate Governance Committees in Teligent.

    On February 16, 2021, William S. Marth, an industry expert, joined Teligent as a member of its Board of Directors. Mr. Marth has experience of 25 years in the pharmaceutical companies as well as manufacturing industries.

    Financial View of TLGT stock:

    • According to the third-quarter results, TLGT stock generated 14.3 million revenue which was 6% higher than the previous quarter due to the high demand for topical products in the U.S.Gross profit of TLGT stock reduced to $0.1 million from $2.4 million in the second quarter of 2020 due to additional expenses related to inventory reserves and other write-offs.
    • Product development and research expenses surged to $2.4 million while selling, general and administrative expenses were $6.5 million in the third quarter of 2020.
    • Operating losses in the third quarter were $8.8 million while the $0.5 million net loss is observed in the third quarter of 2020.

    Conclusion:

    Things are going against the TLGT stock as far as market sentiment is concerned. It seems that momentum was built in the previous trading session but such rises don’t last for a long time.COVID-19 was a major challenge in the continuity of Telligent’s operations, but the management has performed well over the past year. In a nutshell, it would be better for investors to analyze the nitty-gritty of the TLGT stock before taking any decision.